Background: Our previous study suggested that melanoma nuclear protein 18 (Mel-18) acted as a tumor suppressor in human breast cancer. This study was designed to investigate the clinical and prognostic significance of Mel-18 in breast cancer patients.
introduction
Breast cancer is the leading malignancy in women worldwide [1] . Although advance has been dramatic in the treatment for breast cancer, the prognosis of the cancer remains a challenge in the clinic. Factors determining outcomes of breast cancer are complicated including residual diseases, latent metastasis and therapy resistance among many others. There are few tumor markers useful in the monitoring of breast cancer such as CA 15-3, CA 27.29, carcinoembryonic antigen, estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2). The specificity and/or sensitivity of these markers, however, limit their value in the appropriate prediction of prognosis of breast cancer after surgery and after radiotherapy. Therefore, it is necessary to develop novel, yet better, markers that may show increased specificity and/or sensitivity in evaluating the prognosis of breast cancer clinically [2] .
Recently, Polycomb group proteins (PcG) have emerged to be important molecules known to play a crucial role in cancer development, proliferation, senescence, and carcinogenesis [3] . Melanoma nuclear protein 18 (Mel-18, also known as PCGF2), a Polycomb gene originally cloned from B16 mouse melanoma cells, is involved in carcinogenesis [4, 5] , which has been shown to negatively regulate hematopoietic stem cells' activity [6, 7] and inhibit cancer initiation [4] . Bmi-1 (murine leukemia viral insert gene 1), another Polycomb gene, has been reported to have overlapping functions with Mel-18 in cancer growth [4, 8] and cell senescence [9] . Mel-18, different from Bmi-1, can bind to a well-defined nucleotide sequence 5#-GACTNGACT-3# in the promoter region of certain genes such as c-Myc [4] . Because of structural similarity, Mel-18 and Bmi-1 have been suggested to perform very similar functions [10] . Nevertheless, recent studies have indicated that Mel-18 serves as a tumor suppressor gene and inhibits tumor growth through transcriptional repression of Bmi-1 and c-Myc [6, 9] . Furthermore, there are growing evidences indicating that Mel-18 expression is decreased at transcriptional and translational levels in most human breast cancer cell lines [11] . On the other hand, Mel-18 overexpression can reduce the malignancy of MCF-7 cells [12] . Additionally, Mel-18 can negatively regulate INK4a/ARF-independent cell cycle progression via inactivation of Akt in breast cancer cell lines [13] .
Mel-18 is ubiquitously detectable in a number of normal and tumor tissues by microarray analysis [14] . Recent studies have revealed that Mel-18 is down-regulated at transcriptional as well as translational levels in prostate cancer [15, 16] . Additionally, Mel-18 displays a converse correlation with phospho-Akt in primary breast cancer tissues [13] . Our previous studies have also shown a converse correlation between Mel-18 and Bmi-1 in primary breast cancer tissues and adjacent noncancerous tissues [12] . A recently published report has indicated that Mel-18 is decreased in gastric cancer and negatively correlated with Bmi-1 in gastric cancer cells and normal gastric epithelial cells [17] . These findings suggest that Mel-18 may act as a novel tumor suppressor. Interestingly, Mel-18 has also been demonstrated to be highly expressed in other tumors including human melanoma [18] , Hodgkin's lymphoma [19] , benign and malignant myoepithelioma [20] and salivary gland adenoid cystic carcinoma [21] , which points Mel-18 to a contrary function characteristic of an oncogene. Accordingly, we favor the hypothesis that, in terms of carcinogenesis and cancer progression, Mel-18 may function in a cancer type-dependent manner by which collaborating with other molecules, cancer promoting or cancer suppressing, may ultimately determine the functionality of Mel-18 in a particular cancer type.
The present study has focused on the expression patterns of Mel-18 in breast cancer patients with defined clinicopathologic features in a bid to investigate the prognostic value of Mel-18 in breast cancer. We have been able to demonstrate that (i) the decreased expression of Mel-18 is incremental depending upon the magnitude of cancer progression; (ii) the expression patterns of Mel-18 are correlated with clinicopathologic classifications of T, N, M, clinical staging and PR; and (iii) patients with diminished expression of Mel-18 show poor overall survival. These findings strongly suggest that insufficient expression of Mel-18 may serve as a risk factor predictive of prognosis of breast cancer patients following appropriate therapy. ) . Paraffin sections of tissues (4 lm) were deparaffined in xylene and rehydrated in graded alcohols. The sections were then treated with 3% hydrogen peroxide for 10 min to quench the endogenous peroxidase activity. Antigenic retrieval was performed by submerging in EDTA and microwaving. The slides were then allowed to cool at room temperature. Followed by bovine serum albumin to block the nonspecific binding for 15 min at room temperature, the primary antibody was incubated overnight at 4°C. After washing with phosphate-buffered saline, biotinylated secondary antibody was applied for 15 min at 37°C. Then the sections were incubated with streptavidin-horseradish peroxidase complex and developed with 3# diaminobenzidine tetrahydrochloride (DAB). Light Mayer's hematoxylin was applied as a counterstain. The slides were then dehydrated in a series of ethanol and mounted with Resin oil. For negative controls, the primary antibody was replaced by normal rabbit serum. Each section was evaluated by two independent pathologists without knowledge of the clinical features of the cases.
measurements of Mel-18 expression by immunohistochemical assay
All sections were stained in DAB for the same duration of time. For each slide, five random fields were selected for scoring and a mean score of each slide was used in final analyses. Positive staining was accessed using a five scoring system: 0 (no positive cells), 1 (<10% positive cells), 2 (10%-35% positive cells), 3 (36%-70% positive cells), and 4 (>70% positive cells). To achieve objectivity, the intensity of positive staining was also used in a four scoring system: 0 (negative staining), 1 (weak staining exhibited as light yellow), 2 (moderate staining exhibited as yellow brown), and 3 (strong staining exhibited as brown). Mel-18 expression index = (intensity score) · (positive score). The cut-off value for high and low levels of expression was based on a measurement of heterogeneity with a log-rank test statistical analysis with respect to overall survival. Using this assessment system, optimal cut-off values were identified: expression index scores of ‡4 were used to define high expression of Mel-18 and expression index scores of <4 were indicative of low expression of Mel-18. Measurements of ER, PR, and HER-2 expression were routinely performed as previously described [22] .
statistical analyses
All statistical analyses were performed using the SPSS 16.0 statistical software package. Because of the non-normal distribution of protein expression, statistical evaluation was performed using nonparametric tests. Immunohistochemical assay showed that the expression of Mel-18 in the same patient was significantly decreased in primary cancer tissues and corresponding metastatic lymph nodes compared with that in the matched adjacent noncancerous tissues (v 2 = 37.192, P < 0.001; Figure 1 ). As shown in Figure 1 , among those matched adjacent noncancerous tissues, as many as 82.5% (52 of 63) of the individual tissues were stained as either high or strong for Mel-18 (A, B, H, and I panels in Figure 1 ). Of those noncancerous tissues defined as expressing high levels of Mel-18, 44.2% (23 of 52) were stained in the cytoplasm, whereas 55.8% (29 of 52) were in the nucleus. Among breast cancer cases, however, only 52.6% (151 of 287) of the cancer tissues were defined as high expression of Mel-18 ( Figure 1 , Figure 1 . Immunohistochemical analyses of Mel-18 staining. As can be seen, Mel-18 shows strong nuclear staining in matched adjacent noncancer tissues (A, ·100; B, ·400), moderate cytoplasm staining in primary breast cancer tissues (C, ·100; D, ·400) and no positive staining for Mel-18 detectable in corresponding metastatic lymph node tissues (E, ·100; F, ·400) obtained from the same patients. Mel-18 shows increased expression in the adjacent noncancer tissue compared with that in the breast cancer tissues (H, ·100; G, I, ·400). On the other hand, among the corresponding metastatic lymph nodes, a high proportion of the cases (80%) showed negative staining ( Figure 1 , panels E and F) and the remaining 20% (7 of 35) of cases exhibited weak staining, of which these 7 weak staining cases were all restricted to the cytoplasm. An interesting phenomenon was that Mel-18 expression appeared to decrease incrementally with the magnitude of cancer progression in tissues obtained from this patient population ( Figure 1 ).
correlation between decreased expression of Mel-18 and clinical aggressiveness of breast cancer
We further examined possible correlations between expression profiles of Mel-18 and clinical aggressiveness of breast cancer.
As given in Table 1 , analyzing 287 breast cancer cases indicated that the expression profiles of Mel-18 were strongly correlated with clinicopathologic classifications T, N, M, and clinical staging (v 2 test, P < 0.001 for all categories), respectively. These observations suggested a correlation between decreased expression of Mel-18 and clinical progression in breast cancer. Additionally, Mel-18 expression was associated with PR (P = 0.030). On the other hand, our analyses were not able to show such evident correlations between expression profiles of Mel-18 and other clinical and laboratory features including age, expression status of ER, and HER-2.
Mel-18 is associated with an improved prognosis Table S1 (available at Annals of Oncology online) showed the characteristics of breast cancer patients relevant to overall survival. As shown, ER and HER-2 had no value in prognostic assessment in our samples. As expected, however, clinicopathologic classifications T, N, M, and clinical stages were important indicators in the prognosis of breast cancer (P < 0.001). PR status also appeared to have prognostic value clinically (P = 0.002; Table S1 , available at Annals of Oncology online).
Having demonstrated the correlation of Mel-18 expression with clinicopathologic features, we proceeded to examine the relationship between Mel-18 expression and patients' survival. Our analyses indicated a correlation between expressed Mel-18 and survival status of breast cancer patients (P < 0.001; Table  1 ). Kaplan-Meier curves showed that, in the primary breast cancer category, patients expressing higher levels of Mel-18 had prolonged overall survival time (median, 66.95 months), whereas patients expressing lower levels of Mel-18 showed much shorter survival time (median, 35.7 months; log-rank test, P < 0.001; Figure 2A ). The cumulative 5-year survival rate was 89.4% for patients with higher levels of Mel-18 (135 of 151). Surprisingly, the survival rate dramatically dropped to 20.6% for patients with lower levels of Mel-18 (28 of 136). In light of the involvement of Mel-18 in the development of breast cancer, we further analyzed the patients' survival in terms of Mel-18 expression in adjacent noncancerous tissues and corresponding metastatic lymph node tissues. As shown in Figure 2B , examining adjacent noncancerous tissues demonstrated that the overall survival time in patients expressing higher levels of Mel-18 (median, 65.69 months) was much longer than patients expressing lower levels of Mel-18 (median, 38.55 months; log-rank test, P = 0.001). However, analyzing corresponding metastatic lymph nodes suggested that expressed levels of Mel-18 did not seem to have an impact on patients' survival (log-rank test, P = 0.934; Figure 2C ). Furthermore, it remained true that the expression levels of Mel-18 are strongly correlated with patients' survival even after stratifying the patients based upon their clinicopathologic classifications a ( Figure 3A-H) . Interestingly, high Mel-18 expression revealed the favorable impact on outcome irrelevant of the presence of PR by subset analysis ( Figure 3I and J). To determine if Mel-18 could serve as a risk factor with clinical usefulness, we examined overall survival using Cox regression proportional hazard analyses. As seen in Table 2 , univariate Cox regression analyses revealed that lower level of Mel-18 was associated with a significantly increased risk of cancer-related death (P < 0.001) in breast cancer patients. The RRs indicated that tumor size, lymph node metastasis, distant metastasis, and clinical staging were worse predictors. In addition, PR positivity also appeared to be a predictive value in the prognosis of breast cancer (P = 0.005).
After adjusting for potential confounding factors, lower expression of Mel-18 in breast cancer was found to predict poorer survival in an independent manner (P < 0.001; Table 3 ). Analyses using multivariate Cox regression model for clinicopathologic diagnoses (Table 3 ) gave rise to the following results: tumor size, lymph node metastasis, distant metastasis, and clinical staging predicted poor overall survival. The RRs showed no obvious differences when including other clinical parameters such as age, ER, and HER-2 in the analyses using the multivariate Cox regression model (data not shown).
discussion
Mel-18 has been suggested to perform bipolar functions, either as an oncogene or as a tumor suppressor gene, possibly depending upon cell types and/or other molecules interacting with it. This bipolar nature raises cautions when interpreting observed functionality of Mel-18 in the context of carcinogenesis. Mel-18 may act as an oncogene in medulloblastoma as knockdown of Mel-18 results in the inhibition of cell proliferation, loss of transformation, and suppression of tumor formation in DAOY cell line although the exact mechanism(s) remains to be defined [8] . On the contrary, our observations presented here indicate that Mel-18 acts as a tumor suppressor gene in human breast cancer, in keeping with a number of previous reports [12, 13, 15, 16] . Recently, it is reported that Mel-18 negatively regulates INK4a/ARF independent of cell cycle progression via Akt inactivation in breast cancer. Mel-18 can attenuate cell growth and cause G1 arrest by down-regulating cyclin D1 expression and p27 Kip1 phosphorylation at Thr157 via inactivation of the Akt signaling pathway. Mel-18 has been shown to play a role in inhibiting cell growth that is necessary in maintaining cells to achieve a longterm culture [13] . Similarly, we have previously demonstrated that overexpression of Mel-18 results in down-regulated activation of Akt signaling [12] . Prompted by an observation that 1805A polymorphism in the Mel-18 gene plays a crucial role in the progression and metastasis of prostate cancer [15] , we favor the hypothesis that a serious alteration, insertion, and/ or deletion in the gene may be possible to result in diminished [13] . However, in the breast cancer patients as shown in this study, we have not been able to show a correlation between ER status and Mel-18 levels possibly due to disease heterogeneity of breast cancer in a clinical setting. Accordingly, we propose that Mel-18 may perform differential functions largely dependent on the tissue origin of a particular cancer type.
We have shown in this study that Mel-18 expression is decreased in primary breast cancer tissues compared with their adjacent noncancerous tissues. Our observations have been echoed by a previous report [13] . Interestingly and for the first time, we have demonstrated that the expression of Mel-18 is almost undetectable in the corresponding metastatic lymph node tissues ( Figure 1E, F) . Another interesting finding is that Mel-18 shows a descending manner in expression corresponding to the progressive magnitude of breast cancer. Furthermore, Mel-18 expression is reversely correlated with clinicopathologic classifications of breast cancer, which, to the best of our knowledge, has not been reported thus far. Indeed, further analyses of primary cancer tissues have revealed for the first time that breast cancer patients with lower expression of Mel-18 show reduced overall survival than those expressing higher Mel-18, indicating Mel-18's clinical value in assessing the prognosis of breast cancer patients. It should be emphasized that poor survival in patients with lower expression of Mel-18 has been further observed in the adjacent noncancerous tissues, making a stronger argument on the usefulness of Mel-18's assessment value in the prognosis of breast cancer. However, we have not been able to identify a correlation between overall survival and Mel-18 expression in corresponding metastatic [25] . Our findings, together with others', strongly suggest that Mel-18 may be a novel, yet important, prognostic marker for breast cancer patients. Mel-18 has been first isolated as a zinc finger protein and is demonstrated to be localized in the nucleus [18] . Mel-18 interacts with lamin A/C within the nucleus [26] . In reaction lymphoid tissue, Mel-18 shows nuclear staining in a majority of cases with a few cases exhibiting cytoplastic signal [27] . Similarly, Mel-18 is primarily detected in the nucleus and only partially in the cytoplasm after SK-BR-3 cells was transfected with Mel-18 [13] . Interestingly, our study has demonstrated a majority (77.5%) of cases being stained for Mel-18 in the cytoplasm, while only 22.5% of cases showed staining of Mel-18 in the nucleus among our primary breast cancer tissues. In matched adjacent noncancerous tissues, 55.8% of cases have shown nuclear staining for Mel-18. This observation is similar to that observed in prostate cancer tissues of which tissues with high-grade prostate cancer present diminished expression of Mel-18 [15] . Phosphorylation of Polycomb proteins is important for their nuclear localization and/or function as transcriptional repressors or cell cycle regulators. For example, Bmi-1 has been reported to be specifically retained in the chromatin-associated nuclear protein fraction at G1/S of the cell cycle, but phosphorylated Bmi-1 is not chromatin bound during G2/M [28] . Similarly, hyperphosphorylated M33, another mouse polycomb gene, is shown to be localized in the nucleus, whereas hypophosphorylated M33 is localized to the cytoplasm [29] . Early studies have also depicted that phosphorylated form of Mel-18 is associated with the chromatin fraction [30] . We need to further clarify whether phosphorylated Mel-18 plays a role in the discrepant distribution of Mel-18, and whether cytoplastic Mel-18 has different functions.
Clinically, the prognosis of breast cancer heavily relies on T classification, lymph node status, distant metastasis, and clinical staging [31] . Our tests using univariate Cox proportional hazard analysis have revealed N classification to be highly at risk for cancer-related death (Table 2 ). In practice, clinical staging is the most important prognostic factor determined by tumor size, lymph node status, and distant metastasis. Metastasis may occur before lymph node invasion, which may explain a low risk of N classification by multivariate Cox proportional hazard analysis in this patient population [23] . In this respect, detailed investigations of phenotypic heterogeneity in breast cancer may be important in revealing underlying mechanism(s) as to why Mel-18 is involved in the development and progression of breast cancer.
Having demonstrated the significance of Mel-18 expression in the prognosis of overall survival in breast cancer patients, our next focus will be to investigate possible values in cancer-specific survival and/or disease-free survival in terms of Mel-18 levels. Another area worth investigating would be a possible correlation between expressed Mel-18 levels and the outcomes after chemotherapy and hormonal therapy. Nevertheless, it is recommended that expressed levels of Mel-18 may be a choice to be used in prognostic assessment in patients with breast cancer.
In summary, the current study demonstrates that lower Mel-18 expression is correlated with both clinicopathologic classifications and a poor overall survival in breast cancer patients examined. These findings suggest that Mel-18 is a novel marker useful in prognostic assessment for patients with breast cancer. 
